Breast Cancer
Conference Coverage
Chemotherapy better for metastatic breast cancer maintenance than durvalumab
Exploratory analyses showed that patients with triple-negative breast cancer and PD-L1-positive tumors might benefit from durvalumab maintenance...
Opinion
New evidence informs discussions on FL treatment and breast screening
Dr. Alan P. Lyss explores recent studies on rituximab maintenance in follicular lymphoma and the use of MRI as a supplemental screening for women...
Conference Coverage
Oral paclitaxel bests IV version for tumor response, neuropathy incidence in mBC
SAN ANTONIO – An oral formulation of paclitaxel given with the P-glycoprotein pump inhibitor encequidar improved...
Conference Coverage
PEARL lacks luster in metastatic breast cancer progressing on AIs
SAN ANTONIO – Palbociclib plus endocrine therapy was not superior to capecitabine in patients with HR-positive/HER2-...
Conference Coverage
TNBC: Weekly nab-paclitaxel delivers, denosumab disappoints
SAN ANTONIO - Among patients with TNBC who were treated with weekly nab-paclitaxel, 60.4% achieved pCR, compared with 50.0% who were treated with...
Conference Coverage
First report from NeoTRIPaPDL1: No pCR benefit with atezolizumab in TNBC
SAN ANTONIO – Adding atezolizumab, an anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, to neoadjuvant...
Conference Coverage
ctDNA, CTCs predict TNBC relapse – now what?
SAN ANTONIO – Liquid biopsy can identify patients with triple-negative breast cancer at high risk of relapse, but no...
Conference Coverage
CTS5 score partially validated for predicting late distant breast cancer recurrences
SAN ANTONIO – The CTS5 prognostic score is strongly predictive of risk of late distant recurrence of breast cancer in patients over age 50 at...
Conference Coverage
Residual cancer burden linked to long-term survival
SAN ANTONIO – Results from large meta-analysis are expected to alter the American Joint Committee on Cancer (AJCC) staging standards in breast...
Conference Coverage
TNBC: Adding capecitabine boosts disease-free survival in prospective trial
SAN ANTONIO - In a phase 3 trial of 585 women with triple-negative breast cancer, 5-year disease free survival was 86.26% in the capecitabine...